Ahsan N, Groff JA, Diviney LK, Burkholder GA, Waybill MM
Reduction of rHuEPO doses by bolus intravenous iron therapy in
CAPD patients
XVIth Annual CAPD Conference
Perit Dial Int Suppl 2
(Feb) 16:S83 1996
This study examined the effect of bolus intravenous iron (1 g of iron
dextran in 500 ml of 0.5% NaCl given over 3-4 hours) on Hct in
patients on CAPD. The bolus dose was given after an IV test dose and
with premedication (hydrocortisone, acetaminophen, and an
antihistamine). There were adverse or allergic reactions. The
patients chosen for this therapy were moderately iron deficient at
baseline, with TSAT% averaging 10%, and serum ferritin levels
averaging 150 ng/mL.
The TSAT% increased to about 30% at 6 and 12 weeks post infusion, and
ferritin at weeks 6 and 12 post therapy was 430 and 331 ng/mL,
respectively. Acceptable iron saturation was maintained for 6
months, Hct increased, and required EPO dose fell.
Comment: This study supports others now in the literature
that single bolus intravenous iron is beneficial to patients receiving
erythropoietin. This study is confirmatory of another study in
hemodialysis patients. The use of bolus intravenous iron dextran
therapy seems to be on the increase and is an attractive alternative
to frequent IV iron injections, in view of its lower cost and
simplicity. (James L. Winchester, M.D.)
To go back use the BACK button on your browser.
Otherwise click on the desired link to this article below:
XVIth Annual CAPD Conference
CRF by problem area :
Anemia/Erythropoietin/Iron